The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?

Patrice Talaga; Luc Quere

doi:10.2174/1568007023338897

Abstract

The plasma membrane has been the subject of intense investigation in the search for antiamyloidogenic drugs for the treatment of Alzheimers disease. Studies have highlighted numerous toxic properties of the well-known amyloid Aβ peptide on neuronal membranes. In this respect recent experimental data suggest that an early step in amyloid toxicity might be intracellularly mediated. This suggests that effective anti-amyloidogenic agents must be able to readily cross the plasma membrane while at the same time, counteracting the deleterious effects of the Aβ peptide on the phospholipid bilayer. This review summarizes recent findings regarding amyloid-plasma membrane interactions and discusses their relevance for the design of novel, potential anti-Aβ drugs.

Keywords: Aβ, plasma membrane, aggregation, intracellular toxicity, cholesterol, neuroprotection, alzheimer's disease, lipid bilayer